Summary: Researchers have shown that tissue-specific damage in neurodegenerative disease depends on the regional abundance and isoform-specific binding preferences of the partner protein Capicua (CIC). The study demonstrates that CIC-Long (CIC-L) preferentially associates with ATXN1, while CIC-Short (CIC-S) preferentially pairs with ATXN1L (Ataxin-1-like). These distinct isoform partnerships explain why subtle differences in protein interactions lead to localized cellular degeneration and point toward isoform-targeted therapeutic strategies for neurodegenerative disorders.
Key Facts
- Explaining selective vulnerability: Although mutant ATXN1 is expressed broadly across tissues, spinocerebellar ataxia type 1 (SCA1) primarily affects the cerebellum and brainstem. The Baylor and Duncan NRI team found this regional sensitivity is driven by differences in the levels of partner proteins and by isoform-specific binding preferences of CIC.
- Two distinct CIC isoforms: Capicua exists as two main isoforms, CIC-Long (CIC-L) and CIC-Short (CIC-S). Mouse models lacking each isoform exhibit distinct, non-overlapping phenotypes:
- Loss of CIC-S results in early lethality, severe developmental defects (notably in the lungs), and hydrocephalus.
- Loss of CIC-L leads to behavioral changes, cognitive impairments, motor deficits, and hyperactivity.
- Specific binding partnerships: The research identifies precise pairings:
- CIC-L preferentially binds ATXN1. Deleting ATXN1 destabilizes CIC-L and produces cortical and hippocampal phenotypes, including increases in amyloid-beta production that resemble Alzheimer’s-like changes.
- CIC-S preferentially binds ATXN1L. Disruption of the CIC-S/ATXN1L partnership reproduces the developmental and survival defects seen in CIC-S knockout models.
- Cerebellar vulnerability explained: The cerebellum has the highest baseline level of total CIC in the central nervous system. Because mutant, overactive ATXN1 preferentially interacts with CIC-L, a high local abundance of CIC-L in the cerebellum leads to hyper-stabilization of the complex and aberrant transcriptional repression in Purkinje cell networks, driving selective degeneration.
Source: Baylor College of Medicine
Overview
A collaborative team from Baylor College of Medicine and the Duncan Neurological Research Institute at Texas Children’s Hospital reports new mechanistic insights into why some neurological diseases damage specific brain regions despite widespread expression of the disease protein. Their work, published in Genes & Development, uses animal models of spinocerebellar ataxia type 1 (SCA1) to show how isoform-specific protein partnerships and regional protein abundance produce distinct molecular outcomes across tissues.
SCA1 arises from a mutation in the ATAXIN-1 (ATXN1) gene. The mutant ATXN1 protein becomes overly active and accumulates in cells, yet the most severe damage appears in the cerebellum and brainstem. The team focused on Capicua (CIC), a transcriptional repressor and a known ATXN1 partner, to uncover how CIC contributes to this selective toxicity.
Earlier observations showed that removing ATXN1 does not cause ataxia; instead, it leads to learning and memory deficits and increases amyloid-beta production—effects linked to cortex and hippocampus rather than the cerebellum. Conversely, loss of ATXN1L (ataxin-1-like) produces respiratory and developmental failures, perinatal lethality, and hydrocephalus. These divergent consequences implied that ATXN1 and ATXN1L form distinct functional complexes in vivo.
The investigators noted CIC exists in two isoforms that differ at one protein terminus: CIC-L and CIC-S. To test their roles, researchers created mice selectively lacking either CIC-L or CIC-S. The outcomes were striking and isoform-specific: CIC-S deficiency caused severe developmental and survival problems, particularly in the lungs, and hydrocephalus; CIC-L deficiency produced behavioral and cognitive deficits and motor abnormalities without early lethality. This demonstrated the two CIC isoforms perform essential but non-redundant roles.
Biochemical and genetic analyses revealed preferential pairings: CIC-L binds ATXN1 more strongly, while CIC-S favors ATXN1L. Loss of ATXN1 preferentially destabilized CIC-L, aligning with parallel cortical and hippocampal phenotypes seen in ATXN1-deficient animals. The researchers also measured regional protein levels and found that CIC and ATXN1 isoform ratios vary across tissues and developmental stages—for example, the cerebellum has a high CIC-L environment while developing lung tissue shows high CIC-S and ATXN1L—explaining region-specific vulnerabilities when particular partnerships are disrupted.
Taken together, these findings show that subtle differences in the relative abundance of ATXN1, ATXN1L, and CIC isoforms, and the selective complexes they form, produce highly specialized functions and determine which tissues are most susceptible to disease. This mechanistic framework suggests that therapies targeted to specific damaging isoform interactions, rather than wholesale suppression of a protein, could reduce side effects and improve precision in treating SCA1 and related neurodegenerative disorders.
“Our study illuminates an improved understanding of neurological disease and offers new possibilities to comprehend and treat these conditions more effectively,” said the investigators.
Contributors from Baylor College of Medicine and Texas Children’s Hospital include Esmeralda Villavicencio Gonzalez, Elias M. Rivera, Mark A. Durham, Ronald Richman, Elizabeth H.-Y. Chu, Kailey Xia, Hu Chen, Zhandong Liu, Surabi Veeraragavan and Binoy Shivanna.
Funding: Supported by grants from the National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Howard Hughes Medical Institute, and several foundations and endowments.
Key Questions Answered:
A: Mutant ATXN1 requires interaction with Capicua (CIC) to exert toxic effects. The cerebellum contains unusually high levels of CIC, and specifically a high CIC-L to CIC-S ratio. Because ATXN1 preferentially binds CIC-L, mutant ATXN1 hyper-stabilizes ATXN1–CIC-L complexes in the cerebellum, causing aberrant transcriptional repression in vulnerable Purkinje cells and leading to localized degeneration.
A: CIC-L and CIC-S are distinct isoforms that differ at one end of the protein. Mouse models demonstrate they are not interchangeable: CIC-S loss causes lethal developmental defects, while CIC-L loss leads to behavioral and cognitive impairments. Each isoform serves unique biological functions in specific tissues.
A: The discovery that toxicity arises from specific isoform interactions suggests therapies could be designed to disrupt only the harmful complex—such as the ATXN1/CIC-L interaction in the cerebellum—while sparing beneficial protein functions elsewhere. An isoform-specific approach could reduce off-target effects and improve therapeutic precision for SCA1 and similar diseases.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The underlying journal paper was reviewed in full by staff.
- Additional context was added by editorial staff to clarify implications and relevance.
About this neurology and genetics research news
Author: Graciela Gutierrez
Source: Baylor College of Medicine
Contact: Graciela Gutierrez – Baylor College of Medicine
Image: Image credited to Neuroscience News
Original Research: The study appears in Genes & Development.